TrialESMO open2021

SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.

A Bamias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.